Table 2.

K-ras point mutations in pancreatic cancer cell lines and tissues.

Cell lines and cancer tissues	K-ras mutationb	Alteration	Predicated products	Percentage of the mutation in pancreatic cancer tissues among 188 pancreatic cancer casesa
PANC-1	Yes, codon 12	GGT to GAT	GLY to ASP	42.6 % (80/188)
Capan-2	Yes, codon 12	GGT to GTT	GLY to VAL	32.4% (61/188)
MIA PaCa-2	Yes, codon 12	GGT to TGT	GLY to CYS	1.1% (2/188)
BXPC-3	NO	NO	GLY	N/A
HDF	NO	NO	GLY	N/A
Pancreatic cancer patient #1c	Yes, codon 12	GGT to GAT	GLY to ASP	N/A
Pancreatic cancer patient #2c	Yes, codon 12 (two mutations)	GGT to GAT GGT to TGT	GLY to ASP GLY to CYS	N/A
Pancreatic cancer patient #5c	Yes, codon 12	GGT to GTT	GLY to VAL	N/A

^aPercentage of each K-ras codon 12 mutation in pancreatic cancer tissues was summarized from five studies.^{16, 26–29}

^bTypes of K-ras point mutation in PANC-1, Capan-2 and BXPC-3 cell lines were confirmed in our laboratory by sequencing genomic DNA, which was consistent with the previous reports.^26,27

^cPresence of K-ras mutations in pancreatic cancer tissue samples collected in our laboratory was determined by mutant-enriched PCR as described in the Methods. N/A:Not applicable.